
Dr. Leen Kawas Drives EIT Pharma Pipeline Toward Market
Under the leadership of biotech entrepreneur Dr. Leen Kawas, EIT Pharma is moving its late-stage infectious disease therapies closer to commercialization. The company recently achieved a significant milestone as the FDA accepted the New Drug Application for Lonafarnib, a first-in-class oral treatment for chronic hepatitis D.
























